Non-invasive fluorescence sensing reveals changes in intestinal barrier function and gastric emptying rate in a first-in-human study of Crohn's disease

一项首次针对克罗恩病的人体研究发现,非侵入性荧光传感技术能够揭示肠道屏障功能和胃排空速率的变化。

阅读:1

Abstract

BACKGROUND: Crohn's disease is characterised by multifaceted changes in gut function, involving not just inflammatory effects but also alterations in gut barrier function and gastric motility. However, current diagnostic tools used to measure key gut functional parameters are invasive, unreliable or time-consuming. Thus, we applied a novel, non-invasive fluorescence sensing technology - transcutaneous fluorescence spectroscopy (TFS) - to investigate gut barrier function and gastric emptying in Crohn's disease. OBJECTIVES: Our study aimed to validate TFS for non-invasive gastrointestinal (GI) diagnostics and to explore changes in gut barrier function and gastric emptying rate simultaneously in Crohn's disease. DESIGN: A cross-sectional study involving patients with Crohn's disease and healthy individuals. METHODS: We performed fluorescent measurements and lactulose:mannitol (L:M) tests in 38 Crohn's disease patients and 20 healthy volunteers. We investigated multiple TFS-derived parameters as indicators of gut barrier function and gastric emptying rate. Using these parameters, we assessed differences between healthy volunteers, inactive Crohn's patients and active Crohn's patients, and calculated correlations between TFS and L:M values. RESULTS: TFS-derived parameters revealed significantly increased intestinal permeability and delayed gastric emptying in patients with active Crohn's compared to healthy controls. TFS trends showed encouraging alignment with those from the L:M test, suggesting potential concordance with established methods. No adverse events were reported. CONCLUSION: TFS enables rapid, non-invasive discrimination of Crohn's patients from healthy volunteers and allows simultaneous assessment of gut barrier function and gastric emptying rate - two important aspects of GI function in Crohn's disease. This implies potential for improved monitoring and diagnosis of Crohn's disease (and other gut disorders) as well as more advanced study of gut function in health and disease. TRIAL REGISTRATION: The clinical study reported in this article was registered with ClinicalTrials.gov prior to enrolment of the first participant. https://clinicaltrials.gov/study/NCT03434639 and Registration number: NCT03434639.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。